AFMD
Price
$0.63
Change
-$0.08 (-11.27%)
Updated
Apr 3 closing price
Capitalization
10.34M
47 days until earnings call
NTLA
Price
$6.89
Change
-$0.41 (-5.62%)
Updated
Apr 3 closing price
Capitalization
712.2M
27 days until earnings call
Ad is loading...

AFMD vs NTLA

Header iconAFMD vs NTLA Comparison
Open Charts AFMD vs NTLABanner chart's image
Affimed
Price$0.63
Change-$0.08 (-11.27%)
Volume$207.01K
Capitalization10.34M
Intellia Therapeutics
Price$6.89
Change-$0.41 (-5.62%)
Volume$3.89M
Capitalization712.2M
AFMD vs NTLA Comparison Chart
Loading...
AFMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AFMD vs. NTLA commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AFMD is a Hold and NTLA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (AFMD: $0.63 vs. NTLA: $6.89)
Brand notoriety: AFMD and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AFMD: 222% vs. NTLA: 114%
Market capitalization -- AFMD: $10.34M vs. NTLA: $712.2M
AFMD [@Biotechnology] is valued at $10.34M. NTLA’s [@Biotechnology] market capitalization is $712.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AFMD’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • AFMD’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than AFMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AFMD’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • AFMD’s TA Score: 4 bullish, 4 bearish.
  • NTLA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AFMD is a better buy in the short-term than NTLA.

Price Growth

AFMD (@Biotechnology) experienced а -21.49% price change this week, while NTLA (@Biotechnology) price change was -17.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

AFMD is expected to report earnings on May 21, 2025.

NTLA is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($712M) has a higher market cap than AFMD($10.3M). NTLA YTD gains are higher at: -40.909 vs. AFMD (-46.891). AFMD has higher annual earnings (EBITDA): -65.19M vs. NTLA (-523.98M). NTLA has more cash in the bank: 602M vs. AFMD (24.9M). AFMD has less debt than NTLA: AFMD (12.9M) vs NTLA (210M). NTLA has higher revenues than AFMD: NTLA (57.9M) vs AFMD (877K).
AFMDNTLAAFMD / NTLA
Capitalization10.3M712M1%
EBITDA-65.19M-523.98M12%
Gain YTD-46.891-40.909115%
P/E RatioN/AN/A-
Revenue877K57.9M2%
Total Cash24.9M602M4%
Total Debt12.9M210M6%
FUNDAMENTALS RATINGS
AFMD vs NTLA: Fundamental Ratings
AFMD
NTLA
OUTLOOK RATING
1..100
5364
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
9694
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
3950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (25) in the Biotechnology industry is somewhat better than the same rating for AFMD (70). This means that NTLA’s stock grew somewhat faster than AFMD’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AFMD (100). This means that NTLA’s stock grew similarly to AFMD’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as AFMD (99). This means that NTLA’s stock grew similarly to AFMD’s over the last 12 months.

NTLA's Price Growth Rating (94) in the Biotechnology industry is in the same range as AFMD (96). This means that NTLA’s stock grew similarly to AFMD’s over the last 12 months.

AFMD's P/E Growth Rating (95) in the Biotechnology industry is in the same range as NTLA (100). This means that AFMD’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AFMDNTLA
RSI
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 15 days ago
81%
Bullish Trend 12 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
AFMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MAICX8.47N/A
N/A
Victory Trivalent Intl Fd-Core Eq A
OMGNX53.74N/A
N/A
Invesco Main Street R
MYIFX18.23N/A
N/A
Monetta Young Investor Growth
LGASX60.84N/A
N/A
ClearBridge Small Cap FI
PSBMX23.69N/A
N/A
Principal SmallCap R3